Returning to the topic of innovative drugs, Kechuang Bio initially chose the cardiovascular field simply for exploratory purposes.
At the time, I never thought that this field could actually produce any results.
Because there are too many competitors in this field, small molecule drugs have been screened many times, making it difficult to achieve a breakthrough.
It's like trying to pan for gold in a river that has been panned by countless prospectors; it's very difficult to find any.
Surprisingly, it was this seemingly most difficult field that first achieved results and entered the clinical trial stage.
In recent years, due to the prevalence of unhealthy diets, insufficient physical activity, staying up late and smoking, the absolute number of cardiovascular patients in China has been rising continuously.
The direction chosen by Kechuang Biotechnology has a broad market.
Of course, since there are so many patients in this field, it is inevitable that they will be included in centralized procurement.
It's just a matter of time.
"Mr. Zheng, hello. The following is a phase I interim clinical trial report on the MSCI-type myocardial regeneration drug."
......
Myocardial infarction leads to the loss of a large number of functional cardiomyocytes, which is one of the leading causes of death worldwide.
Although various methods such as drug therapy, thrombolysis, coronary artery stenting, and coronary artery bypass grafting have been used clinically to treat myocardial infarction and improve patient survival rates.
However, these methods cannot fundamentally repair a damaged heart or restore its function.
Stem cell transplantation is considered a promising treatment for myocardial infarction.
Significant progress has been made in stem cell transplantation in preclinical and clinical research in recent years.
Stem cell candidates mainly include two categories: pluripotent stem cells and their derivatives, and adult stem cells including hematopoietic stem cells and mesenchymal stem cells.
Mesenchymal stem cells are mesodermal-derived pluripotent stromal cells found in embryonic and adult tissues. They possess the ability to self-renew, have immune privilege, regulate the immune system, and exhibit low tumorigenicity.
To date, mesenchymal stem cells have become the most commonly used cell type in clinical trials due to their safety, multi-differentiation potential, nutritional activity, immunomodulatory properties, and abundant donor sources.
Our MSCI-type myocardial regeneration drug has been shown to effectively induce the expression of mesenchymal stem cells in clinical trials.
Furthermore, since the mesenchymal stem cells are from the patient's own body, this results in better outcomes than traditional mesenchymal stem cell transplantation.
After bone marrow mesenchymal stem cell transplantation, the left ventricular systolic function of patients only increases by 3-10%.
The implanted cells do not survive for long periods of time. In fact, within 24 hours after transplantation, only about 3% of bone marrow mesenchymal stem cells appear in the periphery of the infarcted myocardium, and less than 1% of mesenchymal stem cells survive for more than a week [5].
More importantly, mesenchymal stem cells have difficulty differentiating into cardiomyocytes.
By using MSCI drugs, the systolic function of the left ventricle increased by 23%-37%. After one week of continuous medication, more than 5% of bone marrow mesenchymal stem cells appeared in the marginal area of the infarcted myocardium.
We are still observing specific data on the differentiation of mesenchymal stem cells into cardiomyocytes.
Key steps in the cell therapy procedure, such as in vitro donor selection and expansion, survival, migration, differentiation, and paracrine function in adverse transplantation microenvironments, have been fully optimized.
Based on existing clinical trial data, we can conclude that MSCI-type drugs demonstrate significantly superior therapeutic efficacy compared to traditional stem cell transplantation.
The attachment contains detailed interim reports of the clinical trial...
Zheng Li finished reading the report a month later, and he was very happy at CERN.
Especially after being able to conduct research entirely according to their own wishes.
My understanding of the soul has deepened considerably compared to before.
"Alan, congratulations on your recent new achievements. The impact of this achievement is no less than that of the previous paper."
Kate had tried to hint at her feelings to Zheng Li many times, but she never received the answer she wanted.
Zheng Li didn't show any interest in romantic relationships at all. He would only say a few more words when Kate talked about research-related matters.
"Actually, there has been a lot of speculation about this discovery."
Kate felt a little annoyed because the other person always managed to make a very remarkable discovery sound worthless.
There's always a sense that the other person is showing off, but you can't tell from their face.
Kate said speechlessly, "If this is nothing, then the other researchers at CERN haven't achieved anything."
All the papers I've published since graduating with my doctorate are utterly insignificant.
Kate, who has always been a top student since childhood, has met many Nobel laureates at CERNET.
In Kate's eyes, Zheng Li possessed an extremely keen sense of smell and boundless energy.
Other scientists with a keen sense of smell generally need to rest for a long time after completing their research on a problem.
Kate had never seen anyone like Zheng Li before, who had just proven the existence of higher-dimensional space and then moved on to the next research topic, and even successfully solved it.
Scientific research is not about the ability to solve problems, but about the ability to solve problems.
Of course, some people can make scientific research feel like solving problems, but that kind of research is not very meaningful.
Purposeful research aimed at publishing papers is a matter of opinion.
“I knew beforehand that you would win this year’s Nobel Prize, and now it seems very likely that you will win it all this year.”
This chapter is not finished yet. Please click on the next page to continue reading the exciting content!
Continue read on readnovelmtl.com
